Sanofi SA
SNW
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Stocks News & Analysis
stocks
Anthropic and OpenAI face commodification threats. Here’s what to watch for
Frontier AI labs face a three-pronged set of challenges.
stocks
Berkshire Hathaway: Abel pushes into new territory with Bending Spoons investment
We think it is a sign that the firm is finally moving out of its comfort zone to find places to put capital to work.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,897.60 | 78.10 | -0.87% |
| CAC 40 | 7,868.05 | 88.65 | -1.11% |
| DAX 40 | 25,319.77 | 302.84 | -1.18% |
| Dow JONES (US) | 51,966.03 | 36.38 | -0.07% |
| FTSE 100 | 10,764.69 | 117.21 | -1.08% |
| HKSE | 24,186.83 | 124.11 | 0.52% |
| NASDAQ | 26,430.89 | 290.85 | 1.11% |
| Nikkei 225 | 64,483.37 | 433.33 | -0.67% |
| NZX 50 Index | 13,657.61 | 5.54 | 0.04% |
| S&P 500 | 7,690.73 | 31.29 | 0.41% |
| S&P/ASX 200 | 8,764.60 | 81.10 | -0.92% |
| SSE Composite Index | 3,716.28 | 8.81 | 0.24% |